RT Journal Article
T1 Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy
A1 Sánchez-Muñoz, Alfonso
A1 Alba-Conejo, Emilio
A1 Godoy-Ortiz, Ana
A1 Lendínez-Sanchez, Gonzalo
A1 Pascual, Javier
A1 Zalabardo, Manuel
A1 Cantero, Alexandra
A1 Carabantes, Francisco
A1 Pajares, Bella
A1 Rueda Dominguez, Antonio
A1 Domínguez Recio, María Emilia
A1 Iglesias, Marcos
A1 Villar, Ester
A1 Bermejo, María José
A1 Ribelles, Nuria
A1 Diaz Redondo, Tamara
K1 Mamas - Cáncer
AB Purpose: Evaluate real-world outcomes in three cohorts of patients with early-stage triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC): (1) patients who achieved pathological complete response (pCR); (2) patients without pCR who didn’t receive adjuvant chemotherapy; and (3) patients without pCR who received adjuvant capecitabine.Methods: Retrospective cross-sectional study from two hospitals in Málaga. Patients with TNBC received standard NAC followed by surgery. Between 2004 and 2015, patients not achieving pCR received no further systemic therapy. From 2015 onward, these patients were treated with adjuvant capecitabine. Kaplan–Meier and log-rank tests were used to compare disease-free survival (DFS) and overall survival (OS).Results: A total of 312 patients were included in the study. 133 achieved pCR, 84 patients didn’t achieve pCR and didn’t receive adjuvant capecitabine and 95 patients didn’t reach pCR and received adjuvant capecitabine. 89 patients experienced recurrence and 70 patients died. Patients who achieved pCR had a significantly higher DFS (HR 0.21 CI95% 0.12-0.36, p<0.0001) and higher overall survival (HR 0.27 CI95% 0.15-0.49, p<0.0001) compared to those who didn’t. Statistically significant differences in DFS and OS were observed among the three cohorts (DFS: p<0.00001; OS: p=0.00005). However, no statistically significant differences were found between cohorts 2 and 3 in terms of DFS (p=0.94) or OS (p=0.34).Conclusions: Patients who achieved pCR had better outcomes compared to those who didn’t. Among patients who didn’t achieve pCR, the addition of capecitabine didn’t result in significant improvements in DFS or OS compared to those who didn’t receive adjuvant treatment.
PB Frontiers Media
YR 2025
FD 2025-11-16
LK https://hdl.handle.net/10630/41073
UL https://hdl.handle.net/10630/41073
LA eng
NO Godoy-Ortíz A, Lendínez-Sánchez G, Zalabardo M, Pascual J, López-Pascual A, Cantero A, Ribelles N, Iglesias M, Villar E, Pajares B, Díaz-Redondo T, Domínguez-Recio ME, Carabantes F, Bermejo MJ, Rueda-Domínguez A, Alba E, Sánchez-Muñoz A. Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy. Front Oncol. 2025 Nov 17;15:1648272. doi: 10.3389/fonc.2025.1648272. PMID: 41333222; PMCID: PMC12665565.
NO Este articulo ha sido publicado en la revista Frontiers in Oncology. Esta versión tiene Licencia Creative Commons CC-BY
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026